Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | TNKS | O95271 | 3/20 | 0.49 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20832785 | 0.90 | GPR119 (0.58) | SMN1; SMN2THRBGAAMAPTHDAC3 | |
| SCHEMBL1653095 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2THRBGAAMAPTHDAC3 | |
| SCHEMBL29987909 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2THRBGAAMAPTTLR8 | |
| SCHEMBL20832784 | 0.86 | GPR119 (0.56) | SMN1; SMN2THRBGAAMAPTTLR8 | |
| SCHEMBL20832786 | 0.85 | GPR119 (0.55) | SMN1; SMN2THRBGAAMAPTHDAC6 | |
| SCHEMBL22358456 | 0.85 | TLR8 (0.53) | SMN1; SMN2THRBGAAMAPTHDAC3 | |
| SCHEMBL20820822 | 0.84 | GPR119 (0.54) | SMN1; SMN2THRBGAAMAPTTLR8 | |
| SCHEMBL5633461 | 0.83 | HDAC3 (0.62) | MAPTHDAC3CYP2C9HDAC1HDAC6 | |
| SCHEMBL16399632 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2THRBGAAMAPTTLR8 | |
| SCHEMBL28975838 | 0.82 | GPR119 (0.54) | SMN1; SMN2THRBGAAGPR119HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | SMN1; SMN2 1891/4885THRB 4871/4885GAA 3393/4885 |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | WNT1, TNKS1BP1, TNKS | SMN1; SMN2 4058/4885THRB 1893/4885GAA 1079/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | SMN1; SMN2 2301/4885THRB 2355/4885GAA 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.